FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2738424705> ?p ?o ?g. }

• W2738424705 endingPage "852" @default.
• W2738424705 startingPage "844" @default.
• W2738424705 abstract "BACKGROUND: Disease-modifying therapies (DMTs) are indicated to reduce relapse rates and slow disease progression for relapsing-remitting multiple sclerosis (MS) patients when taken as prescribed. Nonadherence or non-persistence in the real-world setting can lead to greater risk for negative clinical outcomes. Although previous research has demonstrated greater adherence and persistence to oral DMTs compared with injectable DMTs, comparisons among oral DMTs are lacking. OBJECTIVE: To compare adherence, persistence, and time to discontinuation among MS patients newly prescribed the oral DMTs fingolimod, dimethyl fumarate, or teriflunomide. METHODS: This retrospective study used MarketScan Commercial and Medicare Supplemental claims databases. MS patients with ≥ 1 claim for specified DMTs from April 1, 2013, to June 30, 2013, were identified. The index drug was defined as the first oral DMT within this period. To capture patients newly initiating index DMTs, patients could not have a claim for their index drugs in the previous 12 months. Baseline characteristics were described for patients in each treatment cohort. Adherence, as measured by medication possession ratio (MPR) and proportion of days covered (PDC); persistence (30-day gap allowed); and time to discontinuation over a 12-month follow-up period were compared across treatment cohorts. Adjusted logistic regression models were used to examine adherence, and Cox regression models estimated risk of discontinuation. RESULTS: 1,498 patients newly initiated oral DMTs and met study inclusion criteria: fingolimod (n = 185), dimethyl fumarate (n = 1,160), and teriflunomide (n = 143). Patients were similar across most baseline characteristics, including region, relapse history, and health care resource utilization. Statistically significant differences were observed across the treatment cohorts for age, gender, previous injectable/infused DMT use, and comorbidities. Adherence and time to discontinuation were adjusted for age, gender, region, previous oral and injectable/infused DMT use, relapse history, and Charlson Comorbidity Index score. Relative to fingolimod patients, dimethyl fumarate and teriflunomide patients were significantly less likely to have an MPR ≥ 80% (OR = 0.18; 95% CI = 0.09-0.36; P < 0.001 and OR = 0.19; 95% CI = 0.08-0.42; P < 0.001, respectively). Similarly, relative to fingolimod patients, dimethyl fumarate and teriflunomide patients were significantly less likely to have PDC ≥ 80% (OR = 0.47; 95% CI = 0.33-0.67; P < 0.001 and OR = 0.37; 95% CI = 0.23-0.59; P < 0.001, respectively). Additionally, the HR for discontinuation was about 2 times greater for dimethyl fumarate (HR = 1.93; 95% CI = 1.44-2.59; P < 0.001) and teriflunomide patients (HR = 2.27; 95% CI = 1.57-3.28; P < 0.001) compared with fingolimod. CONCLUSIONS: In a real-world setting, patients taking fingolimod had better adherence and persistence compared with patients taking other oral DMTs over 12 months. Coupled with clinical factors, medication adherence and persistence should be important considerations when determining coverage decisions for MS patients. DISCLOSURES: This research was funded by Novartis Pharmaceuticals. Johnson, Lin, Ko, and Herrera are employed by Novartis Pharmaceuticals and own Novartis stock. Huanxue Zhou is employed by KMK Consulting, which provides consulting services to Novartis. Study concept and design were contributed by Johnson, Lin, Ko, and Herrera. Zhou collected the data, and data interpretation was performed by Johnson, Lin, Ko, and Herrera. All authors were involved in manuscript revision. The abstract for this study was presented at the AMCP Nexus 2015; October 26-29, 2015; Orlando, Florida." @default.
• W2738424705 created "2017-07-31" @default.
• W2738424705 creator A5001211507 @default.
• W2738424705 creator A5030838917 @default.
• W2738424705 creator A5063472901 @default.
• W2738424705 creator A5065966188 @default.
• W2738424705 creator A5091247382 @default.
• W2738424705 date "2017-08-01" @default.
• W2738424705 modified "2023-10-05" @default.
• W2738424705 title "Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year" @default.
• W2738424705 cites W104010072 @default.
• W2738424705 cites W172925500 @default.
• W2738424705 cites W1982508920 @default.
• W2738424705 cites W1984705645 @default.
• W2738424705 cites W1999493557 @default.
• W2738424705 cites W2000445173 @default.
• W2738424705 cites W2014094373 @default.
• W2738424705 cites W2036774081 @default.
• W2738424705 cites W2043477263 @default.
• W2738424705 cites W2057780602 @default.
• W2738424705 cites W2061166054 @default.
• W2738424705 cites W2061326496 @default.
• W2738424705 cites W2063223428 @default.
• W2738424705 cites W2063844762 @default.
• W2738424705 cites W2078513771 @default.
• W2738424705 cites W2080458330 @default.
• W2738424705 cites W2133755641 @default.
• W2738424705 cites W2139062201 @default.
• W2738424705 cites W2155441883 @default.
• W2738424705 cites W2162649471 @default.
• W2738424705 cites W2297963658 @default.
• W2738424705 cites W2331354957 @default.
• W2738424705 cites W2746562707 @default.
• W2738424705 cites W76560811 @default.
• W2738424705 doi "https://doi.org/10.18553/jmcp.2017.23.8.844" @default.
• W2738424705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28737986" @default.
• W2738424705 hasPublicationYear "2017" @default.
• W2738424705 type Work @default.
• W2738424705 sameAs 2738424705 @default.
• W2738424705 citedByCount "48" @default.
• W2738424705 countsByYear W27384247052017 @default.
• W2738424705 countsByYear W27384247052018 @default.
• W2738424705 countsByYear W27384247052019 @default.
• W2738424705 countsByYear W27384247052020 @default.
• W2738424705 countsByYear W27384247052021 @default.
• W2738424705 countsByYear W27384247052022 @default.
• W2738424705 countsByYear W27384247052023 @default.
• W2738424705 crossrefType "journal-article" @default.
• W2738424705 hasAuthorship W2738424705A5001211507 @default.
• W2738424705 hasAuthorship W2738424705A5030838917 @default.
• W2738424705 hasAuthorship W2738424705A5063472901 @default.
• W2738424705 hasAuthorship W2738424705A5065966188 @default.
• W2738424705 hasAuthorship W2738424705A5091247382 @default.
• W2738424705 hasBestOaLocation W27384247051 @default.
• W2738424705 hasConcept C104863432 @default.
• W2738424705 hasConcept C118552586 @default.
• W2738424705 hasConcept C126322002 @default.
• W2738424705 hasConcept C151956035 @default.
• W2738424705 hasConcept C167135981 @default.
• W2738424705 hasConcept C201903717 @default.
• W2738424705 hasConcept C2776036978 @default.
• W2738424705 hasConcept C2777703276 @default.
• W2738424705 hasConcept C2778715236 @default.
• W2738424705 hasConcept C2780640218 @default.
• W2738424705 hasConcept C50382708 @default.
• W2738424705 hasConcept C512399662 @default.
• W2738424705 hasConcept C71924100 @default.
• W2738424705 hasConcept C72563966 @default.
• W2738424705 hasConceptScore W2738424705C104863432 @default.
• W2738424705 hasConceptScore W2738424705C118552586 @default.
• W2738424705 hasConceptScore W2738424705C126322002 @default.
• W2738424705 hasConceptScore W2738424705C151956035 @default.
• W2738424705 hasConceptScore W2738424705C167135981 @default.
• W2738424705 hasConceptScore W2738424705C201903717 @default.
• W2738424705 hasConceptScore W2738424705C2776036978 @default.
• W2738424705 hasConceptScore W2738424705C2777703276 @default.
• W2738424705 hasConceptScore W2738424705C2778715236 @default.
• W2738424705 hasConceptScore W2738424705C2780640218 @default.
• W2738424705 hasConceptScore W2738424705C50382708 @default.
• W2738424705 hasConceptScore W2738424705C512399662 @default.
• W2738424705 hasConceptScore W2738424705C71924100 @default.
• W2738424705 hasConceptScore W2738424705C72563966 @default.
• W2738424705 hasIssue "8" @default.
• W2738424705 hasLocation W27384247051 @default.
• W2738424705 hasLocation W27384247052 @default.
• W2738424705 hasOpenAccess W2738424705 @default.
• W2738424705 hasPrimaryLocation W27384247051 @default.
• W2738424705 hasRelatedWork W1532617462 @default.
• W2738424705 hasRelatedWork W2316458168 @default.
• W2738424705 hasRelatedWork W2739756297 @default.
• W2738424705 hasRelatedWork W2904316116 @default.
• W2738424705 hasRelatedWork W2971309441 @default.
• W2738424705 hasRelatedWork W3006777651 @default.
• W2738424705 hasRelatedWork W3030177861 @default.
• W2738424705 hasRelatedWork W4235416836 @default.
• W2738424705 hasRelatedWork W4283512998 @default.
• W2738424705 hasRelatedWork W2291724758 @default.
• W2738424705 hasVolume "23" @default.

• next